EZH2 and neoplasm: Paired-Wilcoxon signed rank test showed a significant increase of EZH2 in metastatic tumor cells compared to primary tumor cells (p = 0.007); EED demonstrated an increased trend in 6 out of 8 paired samples (p = 0.054).